Meta-Analysis of Folic Acid Supplementation Trials on Risk of Cardiovascular Disease and Risk Interaction With Baseline Homocysteine Levels

      Experimental models and observational studies suggest that homocysteine-lowering therapy with folic acid (FA) may prevent cardiovascular disease (CVD). However, FA also stimulates cell proliferation and might promote progression of atherosclerosis. Our objectives were to perform a meta-analysis of FA supplementation trials on CVD events and to explore a potential interaction between FA supplementation and baseline homocysteine levels on CVD events. We searched MEDLINE for randomized controlled trials of FA supplementation to prevent CVD events (January 1966 to July 2009) and performed meta-analyses using random effects models. For trials that reported responses to FA supplementation stratified by baseline levels of homocysteine, we pooled within-trial estimates of differences in log-relative risks by baseline homocysteine levels using a random effects model. Overall, FA supplementation did not affect primary cardiovascular clinical end points (relative risk 1.02, 95% confidence interval [CI] 0.93 to 1.13, p = 0.66) or stroke (relative risk 0.95, 95% CI 0.84 to 1.08, p = 0.43). However, in trials that reported analyses stratified by baseline homocysteine, effect of FA supplementation differed by strata of baseline homocysteine (p for interaction = 0.030). Specifically, risks of primary clinical CVD events comparing FA supplementation to control were 1.06 (95% CI 1.00 to 1.13) in strata with mean baseline homocysteine levels >12 μmol/L and 0.94 (95% CI 0.86 to 1.03) in strata with baseline homocysteine levels <12 μmol/L. In conclusion, FA had no effect on CVD or stroke. However, analysis of within-trial results stratified by baseline homocysteine suggests potential harm in those with high homocysteine at baseline. This interaction may have important implications for recommendations of FA supplement use. In the meantime, FA supplementation should not be recommended as a means to prevent or treat CVD or stroke.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • McCully K.S.
        Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis.
        Am J Pathol. 1969; 56: 111-128
        • Homocysteine Studies Collaboration
        Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis.
        JAMA. 2002; 288: 2015-2022
        • Splaver A.
        • Lamas G.A.
        • Hennekens C.H.
        Homocysteine and cardiovascular disease: biological mechanisms, observational epidemiology, and the need for randomized trials.
        Am Heart J. 2004; 148: 34-40
        • Bazzano L.A.
        • Reynolds K.
        • Holder K.N.
        • He J.
        Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials.
        JAMA. 2006; 296: 2720-2726
        • Spence J.D.
        Homocysteine-lowering therapy: a role in stroke prevention?.
        Lancet Neurol. 2007; 6: 830-838
        • den Heijer M.
        • Willems H.P.
        • Blom H.J.
        • Gerrits W.B.
        • Cattaneo M.
        • Eichinger S.
        • Rosendaal F.R.
        • Bos G.M.
        Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: a randomized, placebo-controlled, double-blind trial.
        Blood. 2007; 109: 139-144
        • Albert C.M.
        • Cook N.R.
        • Gaziano J.M.
        • Zaharris E.
        • MacFadyen J.
        • Danielson E.
        • Buring J.E.
        • Manson J.E.
        Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial.
        JAMA. 2008; 299: 2027-2036
        • Ebbing M.
        • Bleie O.
        • Ueland P.M.
        • Nordrehaug J.E.
        • Nilsen D.W.
        • Vollset S.E.
        • Refsum H.
        • Pedersen E.K.
        • Nygard O.
        Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial.
        JAMA. 2008; 300: 795-804
        • Hodis H.N.
        • Mack W.J.
        • Dustin L.
        • Mahrer P.R.
        • Azen S.P.
        • Detrano R.
        • Selhub J.
        • Alaupovic P.
        • Liu C.R.
        • Liu C.H.
        • Hwang J.
        • Wilcox A.G.
        • Selzer R.H.
        • BVAIT Research Group
        High-dose B vitamin supplementation and progression of subclinical atherosclerosis: a randomized controlled trial.
        Stroke. 2009; 40: 730-736
        • Imasa M.S.
        • Gomez N.T.
        • Nevado Jr, J.B.
        Folic acid-based intervention in non-ST elevation acute coronary syndromes.
        Asian Cardiovasc Thorac Ann. 2009; 7: 13-21
      1. Collins R. SEARCH. (Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine): randomized comparison of folic acid 2 mg plus vitamin B12 1 mg daily versus placebo for 7 years in 12,064 myocardial infarction survivors. Presented at a meeting of the American Heart Association, late breaking trials; New Orleans; November 9, 2008. Available at:

        • Hedges L.V.
        • Olkin I.
        Statistical Methods for Meta-Analysis.
        Academic Press, San Diego, CA1985
        • Higgins J.P.
        • Thompson S.G.
        Quantifying heterogeneity in a meta-analysis.
        Stat Med. 2002; 21: 1539-1558
        • Thompson S.G.
        • Sharp S.J.
        Explaining heterogeneity in meta-analysis: a comparison of methods.
        Stat Med. 1999; 8: 2693-2708
        • Shi J.Q.
        • Copas J.B.
        Meta-analysis for trend estimation.
        Stat Med. 2004; 15: 159-162
        • Moher D.
        • Cook D.J.
        • Eastwood S.
        • Olkin I.
        • Rennie D.
        • Stroup D.F.
        Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement.
        Lancet. 1999; 354: 1896-1900
        • Bonaa K.H.
        • Njolstad I.
        • Ueland P.M.
        • Schirmer H.
        • Tverdal A.
        • Steigen T.
        • Wang H.
        • Nordrehaug J.E.
        • Arnesen E.
        • Rasmussen K.
        • NORVIT Trial Investigators
        Homocysteine lowering and cardiovascular events after acute myocardial infarction.
        N Engl J Med. 2006; 354: 1578-1588
        • Baker F.
        • Picton D.
        • Blackwood S.
        • Hunt J.
        • Erskine M.
        • Dyas M.
        • Ashby M.
        • Siva A.
        • Brown M.
        Blinded comparison of folic acid and placebo in patients with ischemic heart disease: an outcome trial (abstract).
        Circulation. 2002; 106: 741S
        • Liem A.H.
        • van Boven A.J.
        • Veeger N.J.
        • Withagen A.J.
        • Robles de Medina R.M.
        • Tijssen J.G.
        • van Veldhuisen D.J.
        • Folic Acid on Risk Diminishment After Acute Myocardial Infarction Study Group
        Efficacy of folic acid when added to statin therapy in patients with hypercholesterolemia following acute myocardial infarction: a randomised pilot trial.
        Int J Cardiol. 2004; 93: 175-179
        • Lange H.
        • Suryapranata H.
        • De Luca G.
        • Borner C.
        • Dille J.
        • Kallmayer K.
        • Pasalary M.N.
        • Scherer E.
        • Dambrink J.H.
        Folate therapy and in-stent restenosis after coronary stenting.
        N Engl J Med. 2004; 350: 2673-2681
        • Schnyder G.
        • Roffi M.
        • Flammer Y.
        • Pin R.
        • Hess O.M.
        Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart Study: a randomized controlled trial.
        JAMA. 2002; 288: 973-979
        • Toole J.F.
        • Malinow M.R.
        • Chambless L.E.
        • Spence J.D.
        • Pettigrew L.C.
        • Howard V.J.
        • Sides E.G.
        • Wang C.H.
        • Stampfer M.
        Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial.
        JAMA. 2004; 291: 565-575
        • Liem A.
        • Reynierse-Buitenwerf G.H.
        • Zwinderman A.H.
        • Jukema J.W.
        • van Veldhuisen D.J.
        Secondary prevention with folic acid: results of the goes extension study.
        Heart. 2005; 91: 1213-1214
        • Lonn E.
        • Yusuf S.
        • Arnold M.J.
        • Sheridan P.
        • Pogue J.
        • Micks M.
        • McQueen M.J.
        • Probstfield J.
        • Fodor G.
        • Held C.
        • Genest Jr, J.
        • Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators
        Homocysteine lowering with folic acid and B vitamins in vascular disease.
        N Engl J Med. 2006; 354: 1567-1577
        • Guallar E.
        • Silbergeld E.K.
        • Navas-Acien A.
        • Malhotra S.
        • Astor B.C.
        • Sharrett A.R.
        • Schwartz B.S.
        Confounding of the relation between homocysteine and peripheral arterial disease by lead, cadmium, and renal function.
        Am J Epidemiol. 2006; 15: 700-708
        • Loscalzo J.
        Homocysteine trials—clear outcomes for complex reasons.
        N Engl J Med. 2006; 354: 1629-1632
        • Zoccolella S.
        • Iliceto G.
        • deMari M.
        • Livrea P.
        • Lamberti P.
        Management of L-dopa related hyperhomocysteinemia: catechol-O-methyltransferase (COMT) inhibitors or B vitamins? results from a review.
        Clin Chem Lab Med. 2007; 45: 1607-1613
        • Spence J.D.
        • Blake C.
        • Landry A.
        • Fenster A.
        Measurement of carotid plaque and effect of vitamin therapy for total homocysteine.
        Clin Chem Lab Med. 2003; 41: 1498-1504
        • Wright A.J.
        • Dainty J.R.
        • Finglas P.M.
        Folic acid metabolism in human subjects revisited: potential implications for proposed mandatory folic acid fortification in the UK.
        Br J Nutr. 2007; 98: 667-675
        • Cole B.F.
        • Baron J.A.
        • Sandler R.S.
        • Haile R.W.
        • Ahnen D.J.
        • Bresalier R.S.
        • McKeown-Eyssen G.
        • Summers R.W.
        • Rothstein R.I.
        • Burke C.A.
        • Snover D.C.
        • Church T.R.
        • Allen J.I.
        • Robertson D.J.
        • Beck G.J.
        • Bond J.H.
        • Byers T.
        • Mandel J.S.
        • Mott L.A.
        • Pearson L.H.
        • Barry E.L.
        • Rees J.R.
        • Marcon N.
        • Saibil F.
        • Ueland P.M.
        • Greenberg E.R.
        • Polyp Prevention Study Group
        Folic acid for the prevention of colorectal adenomas: a randomized clinical trial.
        JAMA. 2007; 297: 2351-2359
        • Doshi S.N.
        • Moat S.J.
        • McDowell I.F.
        • Lewis M.J.
        • Goodfellow J.
        Lowering plasma homocysteine with folic acid in cardiovascular disease: what will the trials tell us?.
        Atherosclerosis. 2002; 165: 1-3
        • Hankey G.J.
        Is homocysteine a causal and treatable risk factor for stroke?.
        Lancet Neurol. 2007; 6: 751-752
        • Saposnik G.
        • Ray J.G.
        • Sheridan P.
        • McQueen M.
        • Lonn E.
        • Heart Outcomes Prevention Evaluation 2 Investigators
        Homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial.
        Stroke. 2009; 40: 1365-1372
        • Wang X.
        • Qin X.
        • Demirtas H.
        • Li J.
        • Mao G.
        • Huo Y.
        • Sun N.
        • Liu L.
        • Xu X.
        Efficacy of folic acid supplementation in stroke prevention: a meta-analysis.
        Lancet. 2007; 369: 1876-1882
        • Bailey L.B.
        Do low doses of folic acid result in maximum lowering of homocysteine?.
        Am J Clin Nutr. 2005; 82: 717-718
        • Bostom A.G.
        • Selhub J.
        • Jacques P.F.
        • Rosenberg I.H.
        Power shortage: clinical trials testing the “homocysteine hypothesis” against a background of folic acid-fortified cereal grain flour.
        Ann Intern Med. 2001; 135: 133-137
        • Clarke R.
        • Armitage J.
        • Lewington S.
        • Collins R.
        • B-Vitamin Treatment Trialists' Collaboration
        Homocysteine-lowering trials for prevention of vascular disease: protocol for a collaborative meta-analysis.
        Clin Chem Lab Med. 2007; 45: 1575-1581
        • Homocysteine Lowering Trialists' Collaboration
        Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials.
        Am J Clin Nutr. 2005; 82: 806-812

      Linked Article

      • Folic Acid as a Cardiovascular Drug: Dose Matters
        American Journal of CardiologyVol. 106Issue 11
        • Preview
          Edgar et al1 presented in this journal the results of a meta-analysis (14 trials, total n = 38,941) indicating that the administration of folic acid (0.5 to 5 mg/day) has no overall effect on cardiovascular disease (CVD), mortality, or stroke despite a significant decrease in homocysteine (ranging from −13.0% to −38.2%). Analysis of within-trial results suggested an increased CVD risk in patients with high homocysteine levels at baseline and a lower CVD risk in those with lower homocysteine levels at baseline.
        • Full-Text
        • PDF